PET imaging and emerging immunotherapy candidates are beginning to enable image-based therapy personalization for dementia.
A growing number of senior citizens across the globe, as well as the spectrum of society, are affected by dementia due to Alzheimer’s disease (AD). According to the World Health Organization, currently more than 55 million people live with some form of dementia worldwide, 60-70% of which is attributed to AD.1 At first, the onset of cognitive decline can be as subtle as a change in mood or irritability. Many start to suffer from symptoms, such as impairment in linguistic skills, much sooner than receiving their official diagnoses of dementia.
“Accumulation of senile plaques in the brain is the first recognizable sign of Alzheimer’s dementia, followed by neuroinflammation and tauopathy. Beyond that, it starts to affect brain anatomy by neurodegeneration,” says Babak Tousi, MD, a neuro-geriatrician at a world-renowned brain health center based in the midwestern United States. Conventional diagnosis of AD requires exclusion of other potential underlying conditions, making distinctions of similar dementia symptoms and cognitive profiles difficult. Recently, biological factors were added to the AD definition, such as the presence of specific protein abnormalities in the brain. More specifically, these abnormalities include extracellular deposition of amyloid plaques and aggregation of intracellular neurofibrillary tangles due to hyperphosphorylated tau proteins. Amyloid is a generic name of protein debris. In the case of AD, a receptor protein on the neuron called amyloid precursor protein (APP) breaks down into small peptide fragments, and the delayed clearance and aggregation of such debris would cause functional impairment in neurons.2
Examples of amyloid-PET scans. Top: amyloid negative scan. Bottom: amyloid positive scan. Data courtesy of University of Tennessee Medical Center, Knoxville, Tennessee, USA.
“We’re talking about breakdown of
APP, releasing monomers, monomers
attaching to each other to form
oligomers, and oligomers to
protofibrils and ending up as amyloid
plaques. These senile plaques then set
out the inflammatory process and tau
fibrils,” Tousi explains. This idea of
disease progression, wherein amyloid
accumulation triggers the cascade of
neurodegenerative events, is called
amyloid hypothesis.3 “Over the last
couple of decades, most of the
research for discovery of disease-modifying
therapies was focused on
somehow manipulating the cycle of
events associated with amyloid
pathology. For example, some of those
developments focused on beta-secretase
and gamma-secretase,
enzymes that break down amyloid
precursor proteins. Unfortunately,
these studies were unsuccessful.”
Drug discovery and clinical development
This lack of pharmacological intervention, progressive devastation in quality of life, and the associated social costs have propelled the recent drug discovery and clinical development in AD. “There are three different types of pharmacological therapies currently available for Alzheimer’s disease: cognitive enhancers like the cholinesterase inhibitor family and an N-methyl-D-aspartic acid (NMDA) receptor antagonist, medications for management of neuropsychiatric symptoms, and more recently disease-modifying monoclonal antibodies that most of our current research is focused on,” explains Tousi.
The loss of neuronal communication mediated by a neurotransmitter acetylcholine is often observed in the Alzheimer’s brain. “First of all, drugs that can prevent the degradation of acetylcholine in the synapse are shown to provide modest improvement in cognition. The second category is antipsychotic or antidepressants. Such drugs may be administered to manage behavioral symptoms, such as depression, irritability, and agitation, but they will not reverse or slow down the progression of the disease,” Tousi explains. “The third category is about disease-modifying therapeutics. Recently, a therapeutic agent was approved based on the fact that it can decrease amyloid plaques in the brain. We continue to do more trials for this agent as a part of open label study and a new randomized clinical trial, so there’s going to be more safety and efficacy data.”
Many of these disease-modifying therapeutics belong to a class of macro-protein agents called monoclonal antibodies. Monoclonal antibodies are antibodies that are made by selected cultured immune cells that bind to a specific epitope. In the case of AD, the target molecule is a various soluble and insoluble species of APP. When bound by antibodies, these amyloid debris can be recognized by the immune cells and get cleared away.4 Clinical trials showed that treatment with these monoclonal antibodies can reduce amyloid plaques in patients’ brains.5,6
Examples of tau PET scans. Top: tau negative scan. Bottom: tau positive scan. Data courtesy of ADNI database.
Biomarkers for specific targets
In PET brain imaging, radioactive imaging agent for specific targets—or biomarkers—are injected into the patient’s bloodstream, and in vivo accumulation of the biomarker is imaged under a PET camera. As such, the first signs of neuropathological changes can be detected without removal of the brain biopsy specimen. For cognitive disease related to AD, there are two kinds of PET biomarkers approved for clinical use. The first biomarker is an imaging agent used to estimate amyloid neuritic plaque density. Currently, there are three approved amyloid PET imaging biomarkers. The second biomarker targets aggregation of intracellular neurofibrillary tangles due to hyperphosphorylated tau proteins. The U.S. Food and Drug Administration (FDA) approved one such biomarker in May 2020.7
In current clinical trials, these Alzheimer’s imaging biomarkers are used for selecting the suitable patient population that may benefit from investigational drugs being tested. “Clinical trial participants undergo cognitive testing, but aside from that, they undergo amyloid imaging,” explains Tousi. “Based on how much amyloid plaque they have in their brains, they may be qualified to participate in trials to receive antiamyloid therapy.”
The PET biomarker for tau neurofibrillary tangles may have additional value. “Having more amyloid plaque in the brain doesn’t mean that the person is more forgetful than others, simply put. But it seems that the more tau spreading you see, the more likely a person declines in cognition. We have enough study to show that tau PET may reflect cognitive stages across the AD spectrum,” Tousi reports.
“I see some promising results with new anti-amyloid antibody agents under trial.”
Therapeutic trials across the spectrum
The current Alzheimer’s therapeutic trials are enrolling people with a very wide spectrum of cognitive states. “We have some trials for antiamyloid therapy agent for patients with mild cognitive impairment and earlier stage of Alzheimer’s dementia. We also have another multicenter trial in which a drug candidate is tested in healthy, at-risk subjects.” Tousi continues. “These are participants who may only have concerns about their memory problems because of their family history. Even before their symptoms start, they want to explore preventive treatments. For most trials, it is usually a requirement to have PET imaging to confirm the involvement of Alzheimer’s pathologies. Recent studies use amyloid imaging or tau imaging or a combination of both.” Imaging biomarkers therefore serve as a key tool to select target clinical trial participants.
The concept of image-based therapy personalization has been discussed for many years. In oncology, thyroid cancer, neuroendocrine tumors, and prostate cancer are good examples of how imaging can confirm pathologies and contribute to therapy planning. It is curious whether PET imaging also plays a role in determining the patient eligibility for AD therapeutic agents.
“We never had a treatment for AD that required more accurate diagnosis. But if there’s a treatment focused on amyloid pathology, then I think it’s more important to confirm such a problem exists before we start giving treatments,” Tousi says. “It brought up to the surface the fact that we need a biomarker for a diagnosis of Alzheimer’s. Biomarkers have not been a part of clinical diagnostic criteria.” Recently, the International Working Group for the clinical diagnosis of AD proposed including biomarker evidence of Alzheimer’s pathology for clinical diagnosis of AD.8 “We certainly know that there is a vascular component, inflammatory component, and comorbidities from synucleinopathy. A large percentage of patients with Lewy Body dementia may also have Alzheimer’s pathology in autopsy. DaTScan™ is another biomarker that we use to differentiate dementia of Lewy bodies and other types of dementia. If there are more selective biomarkers, they can be helpful.”
Many initial trials targeting removal of cerebral amyloid accumulation failed, leading many to question the validity of amyloid hypothesis. “I see some promising results with new anti-amyloid antibody agents under trial,” Tousi asserts. “These agents seem to remove amyloid plaques and show promising results in cognitive improvement. So, there is some validation coming for the amyloid hypothesis. I think we had the right hypothesis but didn’t have the right targets in the past.”
It appears that the recent development in PET imaging and antibody therapy agents are beginning to enable image-based therapy personalization for dementia. In particular, imaging may help stratify patients who are likely to respond to the treatment from those who do not. In combination with other biomarkers that can indicate the metabolic patterns of the brain or other confounding etiologies of neurodegenerative states, physicians now have a few more tools to make more specific diagnosis and to plan the most suitable treatment for AD.
About the author
Takeshi Shimizu, PhD, is a molecular imaging clinical marketing specialist at Siemens Healthineers. He holds a PhD in biochemistry, microbiology, and molecular biology and worked as a molecular imaging collaboration scientist for Siemens Healthineers in Japan for 10 years prior to assuming his current role.
